First Capital Advisors Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

First Capital Advisors Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,763	Closed	-$265K	–	184
2018 Q3	$265K	Sell	2,763 -200	-7%	-$19.4K	0.16%	129
2018 Q2	$282K	Sell	2,963 -1,263	-30%	-$116K	0.19%	122
2018 Q1	$371K	Sell	4,226 -1,026	-20%	-$93.7K	0.21%	89
2017 Q4	$446K	Buy	5,252 +853	+19%	+$71.5K	0.28%	93
2017 Q3	$381K	Sell	4,399 -4,899	-53%	-$393K	0.26%	99
2017 Q2	$718K	Sell	9,298 -1,390	-13%	-$98.6K	0.49%	60
2017 Q1	$741K	Buy	10,688 +4,099	+62%	+$275K	0.55%	54
2016 Q4	$390K	Buy	+6,589	New	+$407K	0.36%	84

Other funds holding XBI

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

First Capital Advisors Group's XBI Position: Q4 2018 in Review

First Capital Advisors Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 2,763 shares — an estimated $265K sold.

First Capital Advisors Group first reported a position in XBI in Q4 2016 and held it in 8 quarters. The position peaked at $741K in Q1 2017. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

First Capital Advisors Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
First Capital Advisors Group sold 2,763 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $265K.
First Capital Advisors Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 8 quarters.
First Capital Advisors Group's State Street SPDR S&P Biotech ETF position peaked at $741K in Q1 2017.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on First Capital Advisors Group's 13F filing for Q4 2018, filed 7 Feb 2019.